Ashington Innovation to acquire Cell Therapy in a £135 million all-share deal
LONDON, UK: Ashington Innovation (LSE:ASHI), a SPAC that focuses on technology businesses, has announced that it has signed a non-binding term sheet to acquire Cell Therapy Limited, a clinical stage biotechnology firm with a portfolio of patented cellular medicines. Cell…